

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
1	19/YH/0013	255993	Phase 3 - XL184 in Combination with Atezolizumab vs Sorafenib in HCC	11/12/2018	12/08/2019	15/02/2019	18/07/2019	12/08/2019	20/08/2019	16/12/2019	Neither
2	18/NW/0699	241427	TACE-3	14/01/2019	05/09/2019	21/03/2019	23/10/2019	25/10/2019			Sponsor
3	18/EE/0099	239606	CL3-95005-006 SOLSTICE	08/02/2019	01/05/2019	01/06/2018	01/05/2019	03/05/2019	30/05/2019	13/06/2019	Benchmark Met
4	19/SC/0113	241916	Idera 2125-MEL-301	20/07/2017	30/05/2019	24/04/2019	19/06/2019	19/06/2019	19/06/2019	20/06/2019	Benchmark Met
5	18/SS/0010	238051	Erdafitinib compared with Vinflunine or Docetaxel or Pembrolizumab	06/03/2018	04/04/2019	21/03/2018	27/03/2019	09/04/2019	10/04/2019	14/06/2019	Neither
6	18/LO/0745	231612	IL-1 Signal Inhibition in Alcoholic Hepatitis (Isaiah)	21/11/2018	08/04/2019	11/07/2018	03/05/2019	09/05/2019	16/05/2019		Neither
7	18/SC/0242	238151	BLING III study	25/06/2018	09/04/2019	24/08/2018	16/04/2019	18/06/2019	24/06/2019	25/06/2019	Sponsor
8	19/EM/0047	257111	GR40306 (TENAYA): A study of faricimab in nAMD	05/11/2018	10/04/2019	04/04/2019	08/04/2019	15/04/2019	30/04/2019	05/06/2019	Benchmark Met
9	19/NI/0032	242580	3185/0004_Follicular Lymphoma Nordic Nanovector AS	14/01/2019	17/04/2019	01/04/2019	25/04/2019	21/05/2019	16/08/2019		Neither
10	18/WA/0420	246637	Spironolactone for Adult Female Acne	21/01/2019	26/04/2019	04/02/2019	03/06/2019	11/06/2019	24/06/2019	23/07/2019	Sponsor
11	18/LO/1187	240011	ATHENA - a first line ovarian cancer maintenance trial.	31/07/2018	13/05/2019	11/09/2018	19/06/2019	24/06/2019	27/06/2019	16/09/2019	Neither
12	17/YH/0187	218853	PRISM Trial	17/07/2018	24/05/2019	11/10/2017	24/05/2019	17/06/2019	05/07/2019	04/10/2019	Neither
13	18/SW/0045	239151	Mistletoe And Breast Cancer (MAB)	11/06/2018	05/06/2019	02/04/2019	05/06/2019	20/06/2019	30/07/2019	13/09/2019	Neither
14	19/LO/1024	263894	Pembrolizumab ? SBRT in Medically Inoperable Stage I/IIA NSCLC	05/06/2019	05/06/2019	26/07/2019	06/08/2019	16/08/2019	23/08/2019	03/10/2019	Neither
15	18/SS/0085	243640	Alpha-2 agonists for sedation (A2B Trial)	31/05/2019	02/08/2019	14/12/2018	09/08/2019	20/08/2019	12/12/2019	07/01/2020	Sponsor
16	17/LO/1875	219487	Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)	03/07/2018	12/06/2019	08/01/2018	12/07/2019	19/07/2019	24/07/2019	18/10/2019	Neither
17	19/YH/0079	259791	Cabozantinib in Radioiodine-Refractory Differentiated Thyroid Cancer	11/03/2019	19/08/2019	09/05/2019	31/07/2019	19/08/2019	30/08/2019		Neither
18	19/NW/0106	257112	Long-Term safety and efficacy of baricitinib - I4V-MC-JAHV	22/01/2019	14/06/2019	10/06/2019	04/06/2019	14/06/2019	24/06/2019	05/07/2019	Benchmark Met
19	19/EM/0063	253607	AMADEUS	11/03/2019	26/06/2019	14/05/2019	26/06/2019	30/08/2019	02/09/2019	18/09/2019	Both
20	17/EE/0213	201374	Image guided radiotherapy and adaptive brachytherapy for cervix cancer	11/01/2019	05/04/2019	09/10/2017	05/04/2019	05/08/2019	28/10/2019	08/01/2020	Sponsor
21	18/YH/0358	242342	The Sunflower Study	02/10/2018	09/04/2019	12/12/2018	09/04/2019	10/04/2019	10/04/2019	15/04/2019	Benchmark Met
22	18/YH/0236	230191	PROTHOR	13/03/2019	10/04/2019	17/10/2018	10/04/2019	23/04/2019	24/04/2019	20/05/2019	Benchmark Met
23	17/WA/0192	227541	TAME Cardiac Arrest Trial	13/09/2018	11/04/2019	13/06/2018	15/05/2019	17/05/2019	20/05/2019	20/05/2019	Benchmark Met
24	17/SW/0250	222991	Conventional versus minimally invasive extra-corporeal circulation	26/02/2019	29/04/2019	29/11/2017	22/04/2019	17/05/2019	28/05/2019	02/06/2019	Benchmark Met
25	18/WA/0337	248818	TIME: Take home naloxone Intervention Multi centre Emergency setting feasibility trial	17/01/2019	16/05/2019	08/01/2019	16/05/2019	04/06/2019	04/06/2019	04/06/2019	Benchmark Met
26	19/YH/0050	249236	OpTIMUM	08/04/2019	28/05/2019	28/03/2019	28/05/2019	03/06/2019	03/06/2019	26/06/2019	Benchmark Met

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
27	19/NW/0158	259931	Surgery or Cast for Injuries of the Epicondyle in Children's Elbows	05/06/2019	05/06/2019	25/03/2019	25/07/2019	30/07/2019	14/08/2019	17/09/2019	Both
28	18/LO/2111	254025	The FENETRE Study	06/06/2019	07/06/2019	25/03/2019	21/06/2019	21/06/2019	17/10/2019	12/11/2019	Sponsor
29	17/LO/1334	217338	TOXYC: Targeted OXYgen therapy in Critical illness	16/05/2019	25/06/2019	13/11/2017					Study declined
30	19/NW/0174	261666	Biliary Tract Cancer - Durva (TOPAZ-1)	19/03/2019	24/06/2019	28/05/2019	26/07/2019	25/10/2019	12/11/2019	03/12/2019	NHS Provider
31	17/SC/0476	186573	MERIT	25/07/2018	11/07/2019	07/11/2017	25/07/2019	30/07/2019	18/10/2019	04/12/2019	Both
32	19/EE/0105	259619	JUVE-X/ Long term safety and efficacy of baricitinib	10/04/2019	12/07/2019	24/06/2019	28/08/2019	29/08/2019	02/12/2019		Neither
33	18/SC/0342	247085	Phase III Trial of AMT-061 in adults with haemophilia B	14/05/2019	15/07/2019	06/09/2018	09/07/2019	18/07/2019	30/07/2019		Sponsor
34	19/SW/0039	253195	GLOW	30/08/2018	16/07/2019	20/05/2019	30/10/2019	01/11/2019	15/11/2019	30/12/2019	NHS Provider
35	19/EE/0185	260536	FIRST-line support for Assistance in Breathing in Children (FIRST-ABC)	03/06/2019	19/07/2019	26/07/2019	05/09/2019	09/09/2019	07/10/2019	14/10/2019	Sponsor
36	19/LO/0714	246398	Red cell transfusion in Paediatric Allogeneic HSCT (RePAST)	07/05/2019	24/07/2019	24/06/2019	30/08/2019	03/09/2019	03/09/2019	18/09/2019	Benchmark Met
37	19/YH/0067	254066	CANOPY-1	23/03/2019	26/07/2019	23/04/2019	07/08/2019	14/08/2019	19/08/2019		Sponsor
38	19/LO/0952	262142	KEYNOTE-921 - Phase 3 Study of Pembrolizumab plus Docetaxel in mCRPC	08/02/2019	26/07/2019	14/08/2019	05/08/2019	06/08/2019	28/08/2019		Neither
39	19/SC/0253	264426	Open label study of BI 754132 in patients with Geographic Atrophy.	23/05/2019	31/07/2019	08/07/2019	02/08/2019	02/08/2019	20/08/2019	02/10/2019	Benchmark Met
40	18/NE/0282	248188	20170534: Extension of Study 20130173 in Children and Young Adults with OI	22/08/2018	05/08/2019	13/03/2019	16/08/2019	16/08/2019	20/08/2019	09/10/2019	Benchmark Met
41	19/SC/0086	249778	A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors	19/10/2018	05/08/2019	06/06/2019	02/10/2019	07/11/2019	07/11/2019		Sponsor
42	19/NI/0110	260538	EluNIR HBR study	25/03/2019	05/08/2019	19/07/2019	04/08/2019	19/08/2019	25/08/2019	20/09/2019	Benchmark Met
43	19/EM/0020	252705	TAPER	03/07/2019	21/08/2019	23/05/2019	22/08/2019	27/08/2019	11/10/2019		Sponsor
44	19/NW/0442	262204	JUVE BRIGHT	18/06/2019	28/08/2019	06/08/2019	29/08/2019	02/09/2019	18/09/2019	31/10/2019	Benchmark Met
45	19/YH/0158	262107	TRANSITION	13/06/2019	28/08/2019	26/07/2019	04/09/2019	12/09/2019	03/10/2019	12/11/2019	Sponsor
46	19/LO/1057	261202	Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC (KEYNOTE-641)	08/02/2019	30/08/2019	28/08/2019	02/09/2019	12/09/2019	12/09/2019	29/10/2019	Benchmark Met
47	18/NW/0694	248847	Derby - Geographic Atrophy secondary to AMD	06/08/2018	30/08/2019	07/12/2018	02/09/2019	02/09/2019	13/11/2019	13/01/2020	Sponsor
48	19/YH/0247	266732	4451-STEP TEENS-semaglutide effect in adolescents with obesity	24/07/2019	27/09/2019	25/09/2019	30/10/2019	06/11/2019	12/11/2019	15/01/2020	Neither
49	16/SC/0651	213404	High Energy High Protein Peptide Feed Study	01/08/2019	06/09/2019	13/01/2017	12/09/2019	13/09/2019	03/10/2019	12/11/2019	Benchmark Met
50	17/LO/1476	224732	A phase 2a Study in Adult Volunteers with Sickle Cell Anaemia - 001	20/06/2019	09/09/2019	19/10/2017	04/09/2019	10/09/2019	12/09/2019	16/10/2019	Benchmark Met

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
51	19/NW/0443	264683	JAHU; Oral baricitinib in patients 1-18 years with systemic JIA	25/06/2019	11/09/2019	19/08/2019	14/10/2019	14/10/2019	06/11/2019		Neither
52	19/LO/0928	262406	Pembrolizumab+Olaparib vs Abiraterone Acetate or Enzalutamide in mCRPC	31/05/2019	12/09/2019	10/09/2019	10/10/2019	16/10/2019	17/10/2019	20/02/2020	Neither
53	17/LO/0980	219505	HALT - Stereotactic Body Radiotherapy for the treatment of OPD	02/09/2019	19/09/2019	10/07/2017	02/12/2019	02/12/2019	03/12/2019		NHS Provider
54	19/NW/0482	269475	Kepler	18/06/2019	20/09/2019	27/09/2019	09/10/2019	14/10/2019	17/10/2019	05/11/2019	Benchmark Met
55	19/EM/0151	259687	Cerebral Palsy-0075/0140-Teva	19/02/2019	23/09/2019	16/07/2019	14/10/2019	18/10/2019	25/10/2019		Neither
56	19/YH/0099	257815	LAT8881 in Neuropathic Pain	30/11/2018	26/09/2019	05/09/2019	26/09/2019	01/10/2019	19/11/2019	12/12/2019	Sponsor
57	18/SC/0427	220853	The Bronchiolitis Endotracheal Surfactant Study (BESS)	21/06/2019	30/09/2019	15/10/2018	30/09/2019	01/10/2019	10/10/2019	20/11/2019	Benchmark Met
58	19/SC/0415	269249	MELODY	20/08/2019	04/10/2019	04/10/2019	17/10/2019	18/10/2019	06/11/2019		Neither
59	19/SC/0416	269256	Medley D5290C00005	20/08/2019	04/10/2019	04/10/2019	17/10/2019	18/10/2019	29/10/2019		Neither
60	19/LO/1367	266879	Cancer-0456/0232-Regeneron	04/06/2019	04/10/2019	04/10/2019	16/12/2019	19/12/2019	24/12/2019	03/01/2020	Both
61	19/YH/0301	268446	A Phase 2 study of ABBV-3067 alone and in combination with ABBV-2222	05/07/2019	27/11/2019	31/10/2019					Sponsor declined
62	19/SC/0112	259372	ADJUST	09/05/2019	16/12/2019	12/11/2019	18/12/2019	18/12/2019			Not yet 70 days
63	19/LO/1551	269540	NETTER-2	26/09/2019	20/12/2019	06/12/2019	26/12/2019	28/01/2020	04/02/2020		Sponsor
64	19/SW/0166	268532	REVIVAL Trial	17/01/2019	02/01/2020	01/11/2019	02/01/2020	04/02/2020	06/02/2020	28/02/2020	Benchmark Met
65	19/LO/1153	262506	Fostamatinib disodium in the treatment of wAIHA	17/06/2019	07/01/2020	16/09/2019					Both
66	19/NW/0135	252254	COSI	13/05/2019	08/01/2020	17/05/2019	04/03/2020	04/03/2020			Sponsor
67	19/WA/0209	266031	ASICS v1.0	02/08/2019	09/01/2020	04/09/2019	13/02/2020	13/02/2020	09/03/2020		Sponsor
68	19/LO/1336	256748	SIOP-HRMB	18/11/2019	15/01/2020	13/11/2019					Sponsor
69	19/NW/0018	232386	Evaluation of Ketoflo	17/10/2018	24/01/2020	15/03/2019	20/02/2020	24/02/2020	24/02/2020		Not yet 70 days
70	19/ES/0126	271121	RAGNAR - 42756493CAN2002	19/08/2019	28/01/2020	01/11/2019	28/01/2020	28/01/2020	29/01/2020	31/01/2020	Benchmark Met
71	19/EE/0322	265824	The PARROT-2 Trial	20/01/2020	31/01/2020	11/11/2019	07/02/2020				Not yet 70 days
72	19/LO/1866	270431	PLUTO	17/09/2019	05/02/2020	22/12/2019	24/02/2020	24/02/2020			Not yet 70 days
73	19/NW/0032	239520	ELEMENT	01/08/2019	07/02/2020	20/02/2019	07/02/2020	10/02/2020	14/02/2020		Not yet 70 days
74	20/WA/0054	264043	Status Assessment of Participants enrolled in TOWER study	10/01/2020	17/02/2020	06/02/2020	21/02/2020	24/02/2020	05/03/2020	17/03/2020	Benchmark Met
75	18/SW/0254	248635	Short term Water-only Fasting prior to chemotherapy Trial (SWiFT)	13/12/2019	19/02/2020	25/01/2019	04/03/2020	04/03/2020	09/03/2020		Not yet 70 days
76	19/NW/0716	273613	A Study Evaluating the Safety of Elexacaftor Combination Therapy	17/10/2019	04/03/2020	17/01/2020	18/03/2020	19/03/2020	24/03/2020		Not yet 70 days
77	18/SC/0610	242511	POPPY	18/12/2019	05/03/2020	08/01/2019	05/03/2020				Not yet 70 days
78	16/EE/0514	207302	ATOMIC-Meso Phase 2/3 Study	05/02/2020	16/03/2020	28/02/2017					Not yet 70 days
79	20/EE/0101	281712	RECOVERY trial	17/03/2020	23/03/2020	17/03/2020	23/03/2020	26/03/2020			Not yet 70 days
80	19/EM/0086	254831	Open-label Extension Study of IMR-687	05/12/2019	31/03/2020	02/08/2019	07/05/2020				Not yet 70 days